In vitro CYP3A4 metabolism: Inhibition by Echinacea purpurea and choice of substrate for the evaluation of herbal inhibition

Basic and Clinical Pharmacology and Toxicology

Volumn 103, Issue 5, 2008, Pages 445-449

  Hansen, Torstein Schrøder ^a,b   Nilsen, Odd Georg ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

7 BENZYLOXY TRIFLUOROMETHYLCOUMARIN; 7 BENZYLOXYQUINOLINE; COUMARIN DERIVATIVE; CYTOCHROME P450 3A4; ECHINACEA PURPUREA EXTRACT; ECHINAGARD; HYEPERICUM STADA; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; QUINOLINE DERIVATIVE; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; DRUG INHIBITION; ECHINACEA PURPUREA; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; HERBAL MEDICINE; HYPERICUM PERFORATUM; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; TESTOSTERONE METABOLISM;

BINDING SITES; COUMARINS; CYTOCHROME P-450 CYP3A; ECHINACEA; ENZYME INHIBITORS; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; INHIBITORY CONCENTRATION 50; KETOCONAZOLE; PLANT EXTRACTS; QUINOLINES; TESTOSTERONE;

ECHINACEA PURPUREA;

EID: 53949122693     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00307.x     Document Type: Article

References (29)

1. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van RM et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998 280 : 1569 75.
2. Kennedy J. Herb and supplement use in the US adult population. Clin Ther 2005 27 : 1847 58.
3. Wilson KM, Klein JD, Sesselberg TS, Yussman SM, Markow DB, Green AE et al. Use of complementary medicine and dietary supplements among U.S. adolescents. J Adolesc Health 2006 38 : 385 94.
4. Ernst E. St John's wort supplements endanger the success of organ transplantation. Arch Surg 2002 137 : 316 9.
5. Chougnet A, Stoessel C, Woggon WD. Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4). Bioorg Med Chem Lett 2003 13 : 3643 5.
6. Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 2001 12 : 505 13.
7. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998 46 : 101 10.
8. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001 4 : 176 84.
9. Tsukamoto S, Aburatani M, Ohta T. Isolation of CYP3A4 inhibitors from the black cohosh (Cimicifuga racemosa). Evid Based Complement Alternat Med 2005 2 : 223 6.
10. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000 7 : 273 82.
11. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA et al. The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004 75 : 89 100.
12. Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 2004 11 : 98 104.
13. Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 2007 100 : 23 30.
14. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 2000 28 : 360 6.
15. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 1999 48 : 716 27.
16. Kligler B. Echinacea. Am Fam Physician 2003 67 : 77 80.
17. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St. John's wort. J Psychopharmacol 2004 18 : 262 76.
18. Crespi CL, Miller VP, Penman BW. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 1997 248 : 188 90.
19. Racha JK, Zhao ZS, Olejnik N, Warner N, Chan R, Moore D et al. Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metab Pharmacokinet 2003 18 : 128 38.
20. Turpeinen M, Korhonen LE, Tolonen A, Uusitalo J, Juvonen R, Raunio H et al. Cytochrome P450 (CYP) inhibition screening: comparison of three tests. Eur J Pharm Sci 2006 29 : 130 8.
21. Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005 11 : 433 9.
22. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000 38 : 111 80.
23. Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 2002 30 : 314 8.
24. Dilmaghanian S, Gerber JG, Filler SG, Sanchez A, Gal J. Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: testosterone and methadone as substrates. Chirality 2004 16 : 79 85.
25. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP et al. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 2000 28 : 1440 8.
26. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 2006 78 : 2131 45.
27. Lu P, Lin Y, Rodrigues AD, Rushmore TH, Baillie TA, Shou M. Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4. Drug Metab Dispos 2001 29 : 1473 9.
28. Modarai M, Gertsch J, Suter A, Heinrich M, Kortenkamp A. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J Pharm Pharmacol 2007 59 : 567 73.
29. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004 76 : 428 40.